This content is machine translated BRAFV600E-mutated metastatic colorectal cancer (mCRC). Evidence for additional benefit of dual blockade An expert panel finds considerable added benefit in the dual-blockade encorafenib combined with cetuximab in the treatment of metastatic colorectal cancer with BRAFV600E mutation after prior systemic therapy. This is…
